Citius Pharmaceuticals Inc (CTXR) - Total Assets
Based on the latest financial reports, Citius Pharmaceuticals Inc (CTXR) holds total assets worth $132.54 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Citius Pharmaceuticals Inc - Total Assets Trend (2011–2025)
This chart illustrates how Citius Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see Citius Pharmaceuticals Inc market capitalisation for the company's overall valuation and market capitalisation.
Citius Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (September 2025)
Citius Pharmaceuticals Inc's total assets of $132.54 Million consist of 21.3% current assets and 78.7% non-current assets. Review Citius Pharmaceuticals Inc total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $22.29 Million | 17.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $92.80 Million | 70.9% |
| Goodwill | $9.35 Million | 7.1% |
Asset Composition Trend (2011–2025)
This chart illustrates how Citius Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See CTXR stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Citius Pharmaceuticals Inc's current assets represent 21.3% of total assets in 2025, a decrease from 100.0% in 2011.
- Cash Position: Cash and equivalents constituted 3.3% of total assets in 2025, down from 100.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 77.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 70.9% of total assets.
Citius Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Citius Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Citius Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.58 | 0.37 | 32.48 |
| Quick Ratio | 0.16 | 0.06 | 32.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-23.33 Million | $-31.50 Million | $113.34 Million |
Citius Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Citius Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.25 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 12.2% |
| Total Assets | $130.94 Million |
| Market Capitalization | $15.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values Citius Pharmaceuticals Inc's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Citius Pharmaceuticals Inc's assets grew by 12.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Citius Pharmaceuticals Inc (2011–2025)
The table below shows the annual total assets of Citius Pharmaceuticals Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $130.94 Million | +12.25% |
| 2024-09-30 | $116.65 Million | +12.59% |
| 2023-09-30 | $103.61 Million | -9.11% |
| 2022-09-30 | $114.00 Million | -19.96% |
| 2021-09-30 | $142.43 Million | +225.38% |
| 2020-09-30 | $43.77 Million | +51.01% |
| 2019-09-30 | $28.99 Million | -6.65% |
| 2018-09-30 | $31.05 Million | +27.17% |
| 2017-09-30 | $24.42 Million | +11.24% |
| 2016-09-30 | $21.95 Million | +2860.11% |
| 2015-09-30 | $741.54K | -52.39% |
| 2014-09-30 | $1.56 Million | +1342.56% |
| 2013-09-30 | $107.97K | +79874.07% |
| 2012-09-30 | $135.00 | -36.32% |
| 2011-09-30 | $212.00 | -- |
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-… Read more